← Eichor
Study identifier: NCT05868525 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Condition: Blunt Cerebrovascular Injury  ·  Sponsor: Loma Linda University

PhasePhase 4
Planned participants98
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

This description comes directly from the study's public registry record.

Talk to the study team

Maryam B Tabrizi, M.D  ·  (909) 558-4286  ·  MTabrizi@llu.edu

Sina Asaadi, M.D  ·  (412) 539-7088  ·  sasaadi@llu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Loma Linda University Medical CenterLoma Linda, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05868525